Balzarini J, Naesens L, Verbeken E, Laga M, Van Damme L, Parniak M, Van Mellaert L, Anné J, De Clercq E
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
AIDS. 1998 Jul 9;12(10):1129-38. doi: 10.1097/00002030-199810000-00004.
Thiocarboxanilide UC-781 is a highly potent and selective non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1, which also has virucidal properties. Recent studies have shown that UC-781 would seem an ideal candidate for application as a vaginal virucide.
To investigate the antiviral potency and stability of UC-781 in a lipophilic gel formulation.
UC-781 was formulated in replens gel at different concentrations and administered intravaginally to rabbits at 5% in replens gel for 10 days. UC-781 was also exposed to temperatures of 4, 37 and 50 degrees C, and to low pH (6.0, 4.3, 2.0 and 1.2). A number of microorganisms were exposed in culture to serial dilutions of UC-781.
The drug was stable under low pH conditions and did not lose its antiviral potency upon 4 h exposure to pH 3.5 (the estimated vaginal pH). UC-781 can be easily formulated into a lipophilic gel (replens; up to 5%) and proved fully stable at 50 degrees C for 30 days. There was no effect on the growth of microorganisms (i.e., Candida and Lactobacillus strains) that are present in the vaginal flora. Neither systemic side-effects, nor local inflammation or damage of the vaginal mucosa or epithelium were observed in rabbits to which 5% UC-781 in replens gel had been administered. UC-781, formulated as 0.5, 0.2 and 0.05% replens gel, and UC-38, alpha-APA and zidovudine, formulated as 0.5 or 0.2% replens gel, were effective in protecting CEM cells in the very beginning against productive HIV-1 replication. This points to an efficient diffusion of the drugs from the lipophilic gel to the hydrophilic culture medium. However, subsequent subcultivations at a dilution rate of 1:10 every 3-4 days resulted in a rapid breakthrough of virus with all drugs except UC-781 in its 0.5 and 0.2% gel formulation. These cultures were fully protected against HIV-1 and remained completely cleared from virus for at least 10 subcultivations.
The virus that emerged under 0.05% UC-781 remained highly sensitive to the NNRTI, including UC-781, in cell culture, suggesting a lack of resistance development under our experimental conditions.
硫代羧酰苯胺UC - 781是一种高效且选择性的HIV - 1非核苷逆转录酶抑制剂(NNRTI),同时还具有杀病毒特性。近期研究表明,UC - 781似乎是一种理想的阴道杀病毒剂候选药物。
研究UC - 781在亲脂性凝胶制剂中的抗病毒效力及稳定性。
将不同浓度的UC - 781制成Replens凝胶制剂,以5%的Replens凝胶制剂经阴道给药于家兔,持续10天。UC - 781还分别暴露于4℃、37℃和50℃温度以及低pH值(6.0、4.3、2.0和1.2)环境中。多种微生物在培养条件下暴露于UC - 781的系列稀释液中。
该药物在低pH条件下稳定,暴露于pH 3.5(估计的阴道pH值)4小时后抗病毒效力未丧失。UC - 781可轻松制成亲脂性凝胶(Replens;浓度高达5%),并在50℃下保持30天完全稳定。对阴道菌群中存在的微生物(即念珠菌和乳酸杆菌菌株)生长无影响。给家兔阴道内给予5% UC - 781的Replens凝胶制剂后,未观察到全身副作用、局部炎症或阴道黏膜或上皮的损伤。制成0.5%、0.2%和0.05% Replens凝胶制剂的UC - 781,以及制成0.5%或0.2% Replens凝胶制剂的UC - 38、α - APA和齐多夫定,在最初阶段均能有效保护CEM细胞免受HIV - 1的有效复制。这表明药物能从亲脂性凝胶高效扩散至亲水性培养基中。然而,随后每3 - 4天以1:10的稀释率进行传代培养时,除0.5%和0.2%凝胶制剂的UC - 781外,所有药物处理的培养物中病毒均迅速突破。这些培养物对HIV - 1具有完全保护作用,且在至少10次传代培养中均未检测到病毒。
在0.05% UC - 781条件下出现的病毒在细胞培养中对包括UC - 781在内的NNRTI仍高度敏感,这表明在我们的实验条件下未产生耐药性。